Results 191 to 200 of about 1,948,743 (254)

Effect of perioperative restrictive and liberal fluid regimens on postoperative nausea-vomiting and quality of recovery in laparoscopic cholecystectomy. [PDF]

World J Gastrointest Surg
Korkusuz M, Et T.
europepmc   +1 more source

NRS-23786 | Board Minutes [Anti-Discrimination NSW]

This series comprises minutes of the Anti Discrimination NSW ...

core  

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

British Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

He was only thirty one. [PDF]

Palliat Support Care
Shapoo N, Boma N.
europepmc   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

Assessing the burden of severe nausea and vomiting of pregnancy or hyperemesis gravidarum and the associated use and experiences of medication treatments: An Australian consumer survey. [PDF]

PLoS One
Wills L, Hsiao HF, Thomas A, Kay-Smith C, Henry A, Grzeskowiak LE.   +5 more
europepmc   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

Emesis in Rodents: Present or Absent? A Critical Review of the Evidence and Implications for the Use of Rodents in Biomedical Research. [PDF]

Biology (Basel)
Alcantara De Sousa G, Nemoto M, Rudd JA, Sanger GJ, Andrews PLR.   +4 more
europepmc   +1 more source

Optimal intrathecal morphine dosing for revision hip arthroplasty: an observational study

Anaesthesia, EarlyView.
Shalini Patel, Vassia Paschou, Jane Quinlan, Ben Kendrick, Nicolas Suarez   +4 more
wiley   +1 more source

Minimal residual disease–guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype

British Journal of Haematology, EarlyView.
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin   +15 more
wiley   +1 more source